Sign in →

Epic Test Code LAB304 Coagulation Factor V Activity Assay, Plasma

Additional Codes

MML Code: FACTV

 

NY State Approved

Yes

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Reporting Name

Coag Factor V Assay, P

Method Name

Optical Clot-Based

Specimen Stability Information

Specimen Type Temperature Time Special Container
Plasma Na Cit Frozen 14 days


Ordering Guidance


Coagulation testing is highly complex, often requiring the performance of multiple assays and correlation with clinical information. For that reason, consider ordering a Coagulation Consultation.



Necessary Information


If priority specimen, mark request form, give reason, and request a call-back.



Specimen Required


Patient Preparation: Patient must not be receiving coumadin (warfarin) or heparin therapy. (If not possible for medical reasons, note on request.)

Collection Container/Tube: Light-blue top (3.2% sodium citrate)

Specimen Type: Platelet-poor plasma

Collection Container/Tube: Light-blue top (3.2% sodium citrate)

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions:

1. Specimen must be collected prior to factor replacement therapy.

2. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing

3. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.

4. Aliquot plasma into a plastic vial, leaving 0.25 mL in the bottom of centrifuged vial.

5. Freeze plasma immediately (no longer than 4 hours after collection) at -20° C or, ideally,  -40° C or below.

Additional Information:

1. Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.

2. Each coagulation assay requested should have its own vial.


Bassett Healthcare Network Clinical Laboratories Note:

Blood Tube Draw Volume
Min 90% draw volume  

Specimen Type

Plasma Na Cit

Specimen Minimum Volume

0.5 mL

Reference Values

>1 month: 70%-165%

<1 month: Normal, full-term and premature newborn infants may have mildly decreased levels (≥30% to 35%) which reach adult levels within 21 days postnatal.

 

*See Pediatric Hemostasis References section in Coagulation Guidelines for Specimen Handling and Processing

Report Available

1 to 2 days

Day(s) Performed

Monday through Saturday

CPT Code Information

85220

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject

Useful For

Diagnosing congenital deficiencies (rare) of coagulation factor V

 

Evaluating acquired deficiencies associated with liver disease, factor V inhibitors, myeloproliferative disorders, and intravascular coagulation and fibrinolysis

 

Investigation of prolonged prothrombin time or activated partial thromboplastin time

Clinical Information

Factor V is a vitamin K-independent protein synthesized in the liver and in other tissues (endothelium, megakaryocytes/platelets). In its thrombin-activated form (factor Va), it serves as an essential cofactor in the prothrombinase enzyme complex, which converts prothrombin to thrombin (the prothrombinase complex consists of the enzyme, activated factor X, factor Va cofactor, a phospholipid surface, and calcium).

 

Deficiency of factor V may cause prolonged prothrombin time and activated partial thromboplastin time and may result in a bleeding diathesis. Plasma biological half-life varies from 12 to 36 hours.

 

Platelets contain 20% to 25% of the factor V in blood. Factor V (also known as labile factor) is highly susceptible to proteolytic inactivation, with the potential for spuriously decreased assay results.

Interpretation

Acquired deficiencies are much more common than congenital.

 

Patients that are congenitally deficient homozygous generally have activity levels less than or equal to10% to 20%.

 

Patients that are congenitally deficient heterozygous generally have activity levels less than or equal to 50%.

 

Congenital deficiency may occur in combined association with factor VIII deficiency.

Cautions

Factor V (labile factor) is highly susceptible to proteolytic inactivation, with the potential for spuriously decreased assay results. In normal individuals, after freeze-thaw of citrate plasma, factor V activity typically may be 10% to 20% less than observed in a fresh plasma specimen, and in occasional individuals, a more marked decrease of factor V activity occurs. Normal results can be regarded as reliable, but decreased factor V activity results need to be correlated with other clinical and laboratory information. Repeat testing may be necessary.

Specimen Retention Time

7 days